Duloxetine and the symptoms and quality of life of patients with irritable bowel syndrome

The effect of duloxetine on symptoms and quality of life in patients with irritable bowel syndrome with moderate to severe symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190404043159N1

Enrollment

Registered

2020-09-18

Start date

2020-10-15

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Irritable Bowel Syndrome. Condition 2: Quality of life. Condition 3: Stress, anxiety and depression. Irritable bowel syndrome Acute stress reaction

Interventions

Intervention 1: Intervention group: Patients in this group will be treated with duloxetine daily at a target dose of 60 mg per day for three months. The severity of symptoms, quality of life and the l

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Men and women aged 18 to 65 years Diagnosis of irritable bowel syndrome by a gastroenterologist Moderate to severe symptoms Conscious consent to participate in the study Have a minimum literacy Absence of depressive disorders, bipolar disorder or psychotic disorders

Exclusion criteria

Exclusion criteria: Diagnosis of any organic disease Failure to take medication regularly Failure to complete the questionnaire Severe side effects Patient request to leave the study

Design outcomes

Primary

Measure	Time frame
Quality of life score. Timepoint: Before and one week after interventions. Method of measurement: Quality of Life Questionnaire for Patients with Irritable Bowel Syndrome.;Anxiety, depression and stress score. Timepoint: Before and one week after interventions. Method of measurement: By The Depression, Anxiety, and Stress Scale – 21 (DASS-21) questionnaire.;Severity of symptoms. Timepoint: Before and one week after interventions. Method of measurement: Irritable Bowel Syndrome Symptoms Severity Questionnaire.	—

Measure

Time frame

Quality of life score. Timepoint: Before and one week after interventions. Method of measurement: Quality of Life Questionnaire for Patients with Irritable Bowel Syndrome.;Anxiety, depression and stress score. Timepoint: Before and one week after interventions. Method of measurement: By The Depression, Anxiety, and Stress Scale – 21 (DASS-21) questionnaire.;Severity of symptoms. Timepoint: Before and one week after interventions. Method of measurement: Irritable Bowel Syndrome Symptoms Severity Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Sharbafchi

Esfahan University of Medical Sciences

sharbafchi@med.mui.ac.ir+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026